Fig. 1: MK801 protects against LPS-treated HUVECs. | Cell Death Discovery

Fig. 1: MK801 protects against LPS-treated HUVECs.

From: NMDARs antagonist MK801 suppresses LPS-induced apoptosis and mitochondrial dysfunction by regulating subunits of NMDARs via the CaM/CaMKII/ERK pathway

Fig. 1

A MTT assay showed MK801 (1, 5, 10 μM) did not affect cell viability in HUVECs. B MTT assay showed MK801 (1, 5, 10 μM) effectively countered viability reduction induced by LPS (20 μg/ml). C Intracellular glutamate and D extracellular glutamate concentrations in HUVECs after treatment with LPS (20 μg/ml) for 24 h in the absence or presence of MK801(1, 5, 10 μM). E Flow cytometry graphs and F analysis of Ca2+ influx in HUVECs with the fluorescent probe Fluo-4-AM in response to LPS (20 μg/ml) and MK801 (1, 5, 10 μM). G Flow cytometry graphs and (H) analysis of ROS production in HUVECs treated with LPS (20 μg/mL) in the absence or presence of MK801 (1, 5, 10 μM) for 24 h. (Data are presented as mean ± SEM, ***P < 0.001, **P < 0.01, *P < 0.05 vs. Control; ###P < 0.001, ##P < 0.01, #P < 0.05 vs. LPS).

Back to article page